Compare Incyte Corporation (INCY) vs Vipshop Holdings Ltd - ADR (VIPS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Incyte Corporation vs Vipshop Holdings Ltd - ADR — how do they compare? Incyte Corporation trades at $115.71 (market cap $23.11B), while Vipshop Holdings Ltd - ADR trades at $14.63 (market cap $7.01B). The key difference: Incyte Corporation is far larger — about 3.3× Vipshop Holdings Ltd - ADR's market cap, and Vipshop Holdings Ltd - ADR pays a 4.25% dividend while Incyte Corporation pays none. Which is the better fit depends on your goals.
| INCY | VIPS | |
|---|---|---|
Market Cap | $23.11B | $7.01B |
Sector | Health | Consumer Cyclical |
52-Week High | $118.52 | $20.68 |
52-Week Low | $67.38 | $12.92 |
Enterprise Value | $19.13B | $3.60B |
Dividend Yield | — | 4.25% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
INCY trades at $115.66, down 1.36% on the day, with a bullish technical signal from moving averages and strong fundamental performance including a 25.02% net income margin for 2025. Recent positive news includes regulatory approvals for Opzelura in Europe and the acquisition of Vega Therapeutics, expanding its hematology portfolio. Revenue grew to $5.14 billion in 2025, with earnings beating expectations in two of the last three quarters.
The outlook remains positive given robust profitability, pipeline advancements, and a majority analyst buy rating, though risks include competitive pressures and reliance on key drug performance. The stock's current price is slightly above the consensus target of $112.78, suggesting near-term consolidation potential amid longer-term growth catalysts.
Vipshop (VIPS) trades at $14.56, up 0.41% on the day, with a bullish technical signal from moving averages. The stock shows strong profitability with a 7.07% net income margin and attractive valuation ratios including a P/E of 6.61. Recent Q1 2026 earnings met expectations, and the company is pursuing growth through an outlet store REIT spin-off strategy. Revenue has stabilized around $106 billion after a slight decline from 2023 peaks.
Outlook remains positive given low valuations and analyst consensus, but risks include competitive pressures in Chinese e-commerce and macroeconomic headwinds. The stock offers value opportunity if execution on outlet strategy drives growth, though investors should monitor revenue trends and industry challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →About Vipshop Holdings Ltd - ADR
Vipshop Holdings Ltd is an online discount retailer for brands in China. The company offers branded products to consumers in China through flash sales on its vipshop.com, vip.com and lefeng.com websites. Flash sales represent an online retail format combining the advantages of e-commerce and discount sales through selling a finite quantity of discounted products or services online for a limited period of time. It deals in a wide range of products and services for consumers specializing in branded cosmetics, apparel, healthcare products, food and other consumer products. Its operating segment includes Vip.com and Shan Shan Outlets. The company generates maximum revenue from Vip.com segment.
Read more on VIPS →
